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SYPHILIS
POCKET GUIDE 
FOR PROVIDERS
SYPHILIS: A PROVIDER’S 
GUIDE TO TREATMENT 
AND PREVENTION
This guide was created to help educate physicians 
and healthcare providers on the diagnosis, 
treatment, and prevention of syphilis. Note that 
images included in this guide depict the symptoms 
of STDs and are intended for educational use.
DEFINITION & TRANSMISSION
Syphilis is a systemic, sexually transmitted disease 
(STD) caused by the Treponema pallidum bacterium.
Syphilis Transmission
Two means of syphilis transmission: sexual and vertical
• Sexual: Person to person via vaginal, 
anal, or oral sex through direct contact 
with syphilis sores or lesions, known 
as a chancre. Chancres occur at the primary 
stage of syphilis and can be found around 
the external genitals or anus, in the vagina 
or rectum, or in or around the mouth.
• Sexual transmission also occurs at the 
secondary stage, mainly by direct contact 
with mucous membrane lesions such 
as condyloma lata and mucous patches.
• Vertical: From infected mother to her unborn 
baby via the bloodstream.
SCREENING
Providers should routinely test for syphilis 
in persons who
• are pregnant (at the first prenatal visit, 
and at the beginning of the third trimester 
and delivery if risk*);
• are sexually active men who have sex 
with men (at least annually and more 
frequently if risk*);
• are living with HIV and are sexually active 
(annually);
• are otherwise considered to be at increased 
risk for syphilis*
*  Risk is described in the USPSTF’s syphilis 
screening recommendations and the CDC STD 
Treatment Guidelines at www.cdc.gov/std/ 
treatment/. Any person with signs or symptoms 
suggestive of syphilis should be tested for 
syphilis. Also, anyone with an oral, anal, 
or vaginal sex partner who has been recently 
diagnosed with syphilis should be tested 
for syphilis.
PRIMARY STAGE
Signs and Symptoms
If left untreated, syphilis progresses in stages. 
The stages are:
Primary
• One or more chancres (usually firm, round, 
small, & painless but can be atypical, subtle 
lesions) thought to appear at site of exposure 
(mainly genital area) ~3 weeks after infection 
(range 10–90 days).
• Chancres can heal on their own in a few days 
to weeks, even without treatment.
• Patient is highly infectious, and in utero 
transmission is likely in pregnant women. 
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SECONDARY STAGE
• Mucocutaneous lesions (most commonly 
rashes) can occur as chancre(s) fade 
~6 weeks after infection (range 3 wks–6 mos).
• Rashes may first appear on the palms 
of hands or the soles of feet, but typically 
appear on trunk & other areas of the body.
• Lesions such as condyloma lata, a moist, 
wart-like lesion found in the genital area 
& mucous patches on the tongue occur 
in ~25% of patients.
• Other common findings: lymphadenopathy 
& constitutional symptoms. Less common: 
patchy alopecia (~10% of patients) & 
neurologic symptoms (1–2% of patients).
• Symptoms clear within 2–6 wks but may take 
up to 3 mos, even without treatment.
• Patient is highly infectious, especially 
if direct contact with a moist lesion. In utero 
transmission is likely in pregnant women.
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LATENT & TERTIARY STAGES
Early latent:
• Patient has reactive nontreponemal 
and treponemal tests within 1 year of onset 
of infection, but no symptoms.
• Patient is potentially infectious, as signs 
of primary & secondary syphilis can reoccur 
and go unnoticed.
Late Latent or Latent of Unknown Duration:
• Patient has reactive nontreponemal and 
treponemal tests ≥1 year after onset 
of infection or onset of infection cannot 
be determined, but no symptoms.
• Patient is not infectious in late latent stage 
but may be in latent of unknown duration 
if onset of infection within past year.
Tertiary:
• Manifestations in skin and bones (gummas), 
& cardiovascular system.
• Patient is not infectious.
*  In utero transmission can occur during ANY 
latent stage of syphilis but is more likely in early 
latent stage.
NEUROSYPHILIS
• Neurosyphilis is a site of infection and can 
occur at any stage of syphilis. The nervous 
system is infected within hours after infection 
but it can take weeks or years before 
symptoms present, if at all.
• All patients with syphilis and neurologic, 
ophthalmologic, or audiologic symptoms 
warrant a careful neurological exam and 
a CSF evaluation via a lumbar puncture (LP).
• All patients at high risk for syphilis presenting 
with neurologic symptoms should be tested 
for syphilis and HIV.
• Early neurosyphilis usually presents a few 
weeks or a few years after onset of infection, 
and can occur at the primary and secondary 
stage. It typically manifests as meningitis that 
can affect cranial nerves (especially VI, VII and 
VIII), and as meningovascular syphilis which 
may present with stroke-like symptoms.
• Late neurosyphilis typically presents 10–30 
years after onset of infection at the late 
latent stage. Manifestations include general 
paresis (chronic meningoencephalitis leading 
to dementia, muscle weakness and paralysis) 
or tabes dorsalis (demyelination of the 
posterior columns of the spinal cord).
OCULAR SYPHILIS
• Ocular syphilis can occur at any stage 
of syphilis.
• Visual complaints consist of vision loss, blurry 
vision, eye pain, eye redness, etc.
• Patients at high risk for STIs who present with 
ocular signs or symptoms should 
be tested for syphilis and HIV.
• Patients with syphilis & ocular symptoms 
should receive a careful neurological exam, 
an ophthalmologic assessment, and CSF 
evaluation via lumbar puncture.
• Treatment should not be delayed while 
awaiting the results of tests as severe 
outcomes, including permanent blindness, 
have been reported.
CONGENITAL SYPHILIS
• All pregnant women should be tested 
for syphilis at their first prenatal visit, 
as required by law in most states.
• Additional testing at the beginning of the 
third trimester (28 weeks) & at delivery 
is indicated if the woman is at increased risk 
or lives in a community with high syphilis 
prevalence rates.
• Pregnant women diagnosed with syphilis 
should be treated with penicillin immediately. 
Treatment ≥30 days prior to delivery is likely 
to prevent most cases of congenital syphilis. 
(It may not prevent stillbirth or congenital 
syphilis in a gravely infected fetus as 
evidenced by fetal syphilis on ultrasound 
at the time of treatment).
• All women who deliver a stillborn infant 
(after 20 weeks) should be tested for syphilis 
at time of delivery.
DIAGNOSIS
• Darkfield examinations & other tests 
(e.g., PCR) to detect T. pallidum directly 
from lesion exudate or tissue are definitive 
methods for diagnosing early syphilis and 
congenital syphilis, though not available 
in most settings.
• Presumptive diagnosis requires use 
of 2 serologic tests: a nontreponemal test 
(i.e., VDRL or RPR) & a treponemal test 
(i.e., FTA-ABS tests, the TP-PA assay, various 
EIAs, chemiluminescence immunoassays, 
immunoblots, or rapid treponemal assays). 
Persons with a reactive nontreponemal test 
should always receive a treponemal test 
to confirm the presumptive diagnosis 
of syphilis.
• Reverse sequence screening algorithm 
for syphilis testing is also used. Positive 
treponemal screening tests are confirmed 
with a standard nontreponemal test with titer. 
More information at www.cdc.gov/mmwr/
preview/mmwrhtml/mm6005a1.htm.
DIAGNOSIS (CONTINUED)
All positive nontreponemal tests must 
be quantified at time of treatment, as titers are 
used to monitor treatment success.
• Note: In primary syphilis, nontreponemal 
serologic tests are only ~75% sensitive.
• Note: In primary & secondary syphilis, 
“prozone effect” is possible (false negative 
RPR occurring when high antibody titers 
prevent antibody/antigen lattice formation).
• All patients with positive syphilis serologic 
tests & a presumptive diagnosis of syphilis 
must be staged to determine the recommended 
treatment regimen. Information needed 
to determine stage: complete sexual 
& medical history including history of syphilis 
testing/treatment; thorough physical exam; 
epidemiologic information such as risk factors 
& sexual partner(s) history of syphilis.
• All patients at risk for syphilis warrant 
a thorough physical exam & sexual history.
DIAGNOSIS (CONTINUED)
• Contact the local health department for 
information about patient’s syphilis testing 
history & partner notification.
• Report presumptive & confirmed cases 
by stage, including any neurologic or ocular 
involvement. Report cases of primary, 
secondary, early latent or congenital syphilis 
within 1 working day of diagnosis.
TREATMENT
Primary, Secondary, or Early Latent 
(<1 year)
• Benzathine penicillin G 2.4 million units 
IM in a single dose
Late Latent (>1 year), Latent Syphilis 
of Unknown Duration, or Tertiary Syphilis 
with Normal CSF Examination
• Benzathine penicillin G 7.2 million units total, 
administered as 3 doses of 2.4 million units 
IM each at 1-week intervals
Pregnant women
• Pregnant women should be treated with 
the penicillin regimen appropriate for their 
stage of infection. (See CDC STD Treatment 
Guidelines)
TREATMENT (CONTINUED)
Neurosyphilis, Ocular Syphilis
• Aqueous crystalline penicillin G 18–24 million 
units per day, administered as 3–4 million 
units IV every 4 hours or continuous infusion, 
for 10–14 days
• Additional doses of benzathine penicillin are 
not indicated in patients with HIV infection.
• Additional doses of penicillin in pregnant 
women with early syphilis may be indicted 
if evidence of fetal syphilis on ultrasound.
Note: For treatment information on congenital 
syphilis and syphilis in children, please see CDC 
STD Treatment Guidelines at www.cdc.gov/std/
treatment/.
Penicillin Allergies
• See CDC STD Treatment Guidelines
Penicillin Shortages
• See www.cdc.gov/std/treatment/drugnotices/
bicillinshortage.htm
PREVENTION
• Correct and consistent use of latex condoms 
can reduce the risk of syphilis when the 
infected area is covered. Since many primary 
lesions in the vagina & rectum go unnoticed, 
consistent condom use for vaginal & anal 
intercourse can reduce the risk of syphilis.
• If sexually active, the surest way to avoid 
transmission of syphilis is to be in a long-term 
mutually monogamous relationship with 
a partner who has been tested and is known 
to be uninfected.
• Most partners are unaware that they have 
been exposed to syphilis until notified 
by a partner, provider, or health department. 
Partner notification (a type of partner-based 
intervention) is a service that can be provided 
by the local health department.
• Sexual partners of infected patients are very 
likely to be infected. They should receive 
preventive treatment per CDC STD Treatment 
Guidelines at the time of visit, without waiting 
for diagnostic results.
FOR MORE INFORMATION:
• Visit www.cdc.gov/std/syphilis/treatment.htm
• Contact your local health department
• Call 1-800-CDC-INFO
• Health care providers with STD consultation 
requests can also contact the STD Clinical 
Consultation Network. This free service 
is provided by the National Network 
of STD Clinical Prevention Training Centers 
& operates 5 days/week. Information 
is available at www.stdccn.org
• A web-based self-study syphilis module 
is available for clinicians at www.std.uw.edu/
go/pathogen-based/syphilis/core-concept/all
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